银化物Rb1可以通过调节FTO介导的m6在NETs诱导的内皮激活中的RNA修饰来减轻动脉样硬化,部分是通过调节NETs诱导的内皮激活中的RNA修饰
Zhenni Yang1, Minqi Xiong1,2, Xinmiao Tang1
1Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Frontiers in pharmacology
|August 7, 2025
概括
银化物Rb1 (Rb1) 通过抑制中性粒细胞外细胞陷 (NETs) 诱导的内皮激活来减少动脉样硬化. 这种保护效应通过调节内皮细胞中FTO依赖的N6-甲基氨酸 (m6A) RNA脱甲基化来调节.
科学领域:
- 心血管生物学 心血管生物学
- 分子医学是分子医学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 金色化物Rb1 (Rb1) 显示出减轻动脉样硬化的潜力.
- 中性粒细胞外细胞陷 (NETs) 在内皮激活和动脉样硬化中的作用越来越被认可.
- 在Rb1的抗动脉样硬化作用中,N6-甲基氨酸 (m6A) RNA修饰的参与仍然不清楚.
研究的目的:
- 调查Rb1是否抑制NETs诱导的内皮激活.
- 为了确定m6ARNA修饰是否在Rb1的抗动脉样硬化作用中具有机械作用.
主要方法:
- 用高脂肪饮食养的Apoe-/-小鼠和人类大动脉内皮细胞 (HAEC) 用于体内和体外研究.
- 进行了组织学,免疫组织学和分子分析.
- 评估了NETs诱导的内皮激活,m6ARNA甲基化和FTO表达.
主要成果:
- 在体内,Rb1减轻了动脉样硬化病变和内皮激活.
- 在体外,Rb1减少了中性粒细胞和单细胞对NETs刺激的HAEC的粘附,抵消了NETs诱导的粘附分子上调 (ICAM1,VCAM1,SELE,SELEP),并保护了内皮屏障功能.
- 在HAEC中,NETs暴露降低了m6ARNA甲基化和增加了FTO表达;Rb1治疗逆转了这些影响.
- 在体外,FTO过度表达取消了Rb1的保护作用,并在体内部分取消了Rb1的益处.
结论:
- Rb1通过抑制NETs诱导的内皮激活来缓解动脉样硬化.
- Rb1的抗动脉样硬化作用部分通过调节内皮细胞中FTO依赖的m6ARNA脱甲基化来调节.
更多相关视频
07:53Standardized Rat Coronary Ring Preparation and Real-Time Recording of Dynamic Tension Changes Along Vessel Diameter
Published on: June 16, 2022
3.3K
07:36Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
Published on: September 26, 2018
10.1K
相关概念视频
Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
509
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
509
